Chris Schott
Stock Analyst at JP Morgan
(3.32)
# 1,005
Out of 4,711 analysts
122
Total ratings
51.9%
Success rate
1.55%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $175.58 | +13.91% | 2 | Nov 13, 2024 | |
| GILD Gilead Sciences | Maintains: Overweight | $100 → $105 | $92.57 | +13.43% | 3 | Nov 7, 2024 | |
| BIIB Biogen | Maintains: Neutral | $220 → $210 | $146.47 | +43.37% | 3 | Nov 4, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,200 → $1,150 | $701.85 | +63.85% | 5 | Oct 24, 2024 | |
| TEVA Teva Pharmaceutical | Maintains: Neutral | $16 → $18 | $22.09 | -18.52% | 15 | Oct 21, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $630 → $575 | $412.26 | +39.48% | 7 | Oct 11, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $164.84 | +39.53% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $1,050 → $1,100 | $767.76 | +43.27% | 20 | Sep 13, 2024 | |
| OGN Organon & Co. | Downgrades: Underweight | $18 → $20 | $14.58 | +37.17% | 2 | Sep 6, 2024 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Neutral | $9 | $7.78 | +15.68% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $41 | $25.75 | +59.22% | 11 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $24.92 | +68.54% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $263.38 | +2.51% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $26.36 | +28.98% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $98.05 | +27.49% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $12.52 | +11.82% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.52 | +623.68% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $11.63 | +71.97% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.47 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $57.33 | +36.05% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $5.92 | +15,947.30% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.11 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $18.98 | +163.44% | 3 | Nov 2, 2018 |
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $175.58
Upside: +13.91%
Gilead Sciences
Nov 7, 2024
Maintains: Overweight
Price Target: $100 → $105
Current: $92.57
Upside: +13.43%
Biogen
Nov 4, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $146.47
Upside: +43.37%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Overweight
Price Target: $1,200 → $1,150
Current: $701.85
Upside: +63.85%
Teva Pharmaceutical
Oct 21, 2024
Maintains: Neutral
Price Target: $16 → $18
Current: $22.09
Upside: -18.52%
IDEXX Laboratories
Oct 11, 2024
Maintains: Overweight
Price Target: $630 → $575
Current: $412.26
Upside: +39.48%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $164.84
Upside: +39.53%
Eli Lilly
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $767.76
Upside: +43.27%
Organon & Co.
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $14.58
Upside: +37.17%
Amneal Pharmaceuticals
Sep 6, 2024
Upgrades: Neutral
Price Target: $9
Current: $7.78
Upside: +15.68%
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $25.75
Upside: +59.22%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $24.92
Upside: +68.54%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $263.38
Upside: +2.51%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $26.36
Upside: +28.98%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $98.05
Upside: +27.49%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $12.52
Upside: +11.82%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.52
Upside: +623.68%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $11.63
Upside: +71.97%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.47
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $57.33
Upside: +36.05%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $5.92
Upside: +15,947.30%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.11
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $18.98
Upside: +163.44%